View in EDS HTML Full Text PDF Full Text

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.

Saved in:

Bibliographic Details
Title:	Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.
Authors:	Bittner, Madison¹ (AUTHOR), Llaurado Fernandez, Marta^1,2 (AUTHOR), Hoenisch, Joshua^1,3 (AUTHOR), Leung, Yuen Yee^1,4 (AUTHOR), Kim, Hannah^1,5 (AUTHOR), Wong, Nelson K. Y.^2,6 (AUTHOR), Pishas, Kathleen I.^3,4,7 (AUTHOR), Cheasley, Dane^3,4,8 (AUTHOR), Cowley, Karla J.^5,9 (AUTHOR), Simpson, Kaylene J.^1,5 (AUTHOR), Lin, Yen-Yi^2,6,7 (AUTHOR), Volik, Stanislav^3,6 (AUTHOR), Le Bihan, Stephane^4,6 (AUTHOR), Collins, Colin C.^5,6,7 (AUTHOR), Köbel, Martin^6,8 (AUTHOR), Carey, Mark S.^1,7,9 (AUTHOR)
Source:	International Journal of Molecular Sciences. Feb2026, Vol. 27 Issue 4, p1774. 24p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	16616596
DOI:	10.3390/ijms27041774